RhumbLine Advisers’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-94,082
| Closed | -$4.86M | – | 3071 |
|
|
2022
Q3 | $4.86M | Buy |
94,082
+11,581
| +14% | +$479K | 0.01% | 1251 |
|
|
2022
Q2 | $2.04M | Buy |
82,501
+8,950
| +12% | +$197K | ﹤0.01% | 1756 |
|
|
2022
Q1 | $1.84M | Sell |
73,551
-7,819
| -10% | -$220K | ﹤0.01% | 1859 |
|
|
2021
Q4 | $2.96M | Sell |
81,370
-1,121
| -1% | -$39.4K | ﹤0.01% | 1669 |
|
|
2021
Q3 | $1.41M | Buy |
82,491
+2,032
| +3% | +$31.7K | ﹤0.01% | 2073 |
|
|
2021
Q2 | $1.08M | Buy |
80,459
+21,052
| +35% | +$519K | ﹤0.01% | 2213 |
|
|
2021
Q1 | $3.04M | Sell |
59,407
-7,231
| -11% | -$435K | ﹤0.01% | 1692 |
|
|
2020
Q4 | $4.13M | Buy |
66,638
+5,025
| +8% | +$288K | 0.01% | 1467 |
|
|
2020
Q3 | $3.38M | Sell |
61,613
-11,310
| -16% | -$609K | 0.01% | 1401 |
|
|
2020
Q2 | $4.2M | Buy |
72,923
+11,991
| +20% | +$653K | 0.01% | 1306 |
|
|
2020
Q1 | $2.45M | Buy |
60,932
+6,558
| +12% | +$278K | 0.01% | 1435 |
|
|
2019
Q4 | $2.15M | Buy |
54,374
+7,763
| +17% | +$136K | ﹤0.01% | 1766 |
|
|
2019
Q3 | $316K | Buy |
46,611
+210
| +0.5% | +$1.58K | ﹤0.01% | 2553 |
|
|
2019
Q2 | $432K | Buy |
46,401
+16,697
| +56% | +$193K | ﹤0.01% | 2420 |
|
|
2019
Q1 | $413K | Sell |
29,704
-892
| -3% | -$10.2K | ﹤0.01% | 2406 |
|
|
2018
Q4 | $334K | Buy |
30,596
+9,479
| +45% | +$100K | ﹤0.01% | 2483 |
|
|
2018
Q3 | $267K | Sell |
21,117
-1,250
| -6% | -$15.1K | ﹤0.01% | 2577 |
|
|
2018
Q2 | $295K | Sell |
22,367
-1,211
| -5% | -$14.5K | ﹤0.01% | 2542 |
|
|
2018
Q1 | $321K | Sell |
23,578
-405
| -2% | -$4.18K | ﹤0.01% | 2400 |
|
|
2017
Q4 | $143K | Sell |
23,983
-5,970
| -20% | -$41K | ﹤0.01% | 2718 |
|
|
2017
Q3 | $222K | Buy |
29,953
+705
| +2% | +$5.86K | ﹤0.01% | 2681 |
|
|
2017
Q2 | $274K | Sell |
29,248
-95
| -0.3% | -$697 | ﹤0.01% | 2604 |
|
|
2017
Q1 | $214K | Buy |
29,343
+868
| +3% | +$6.25K | ﹤0.01% | 2633 |
|
|
2016
Q4 | $211K | Buy |
28,475
+1,753
| +7% | +$12.6K | ﹤0.01% | 2649 |
|
|
2016
Q3 | $161K | Buy |
26,722
+776
| +3% | +$3.67K | ﹤0.01% | 2738 |
|
|
2016
Q2 | $116K | Sell |
25,946
-2,689
| -9% | -$10.1K | ﹤0.01% | 2895 |
|
|
2016
Q1 | $71K | Hold |
28,635
| – | – | ﹤0.01% | 2939 |
|
|
2015
Q4 | $232K | Buy |
28,635
+2,120
| +8% | +$15K | ﹤0.01% | 2717 |
|
|
2015
Q3 | $160K | Buy |
26,515
+917
| +4% | +$6.63K | ﹤0.01% | 2859 |
|
|
2015
Q2 | $211K | Sell |
25,598
-12,115
| -32% | -$96.2K | ﹤0.01% | 2867 |
|
|
2015
Q1 | $285K | Buy |
37,713
+1,800
| +5% | +$14.1K | ﹤0.01% | 2647 |
|
|
2014
Q4 | $245K | Buy |
35,913
+3,250
| +10% | +$17.2K | ﹤0.01% | 2694 |
|
|
2014
Q3 | $147K | Hold |
32,663
| – | – | ﹤0.01% | 2861 |
|
|
2014
Q2 | $191K | Buy |
32,663
+12,038
| +58% | +$67.6K | ﹤0.01% | 2857 |
|
|
2014
Q1 | $137K | Sell |
20,625
-1,200
| -5% | -$8.34K | ﹤0.01% | 2878 |
|
|
2013
Q4 | $126K | Sell |
21,825
-700
| -3% | -$3.61K | ﹤0.01% | 2939 |
|
|
2013
Q3 | $125K | Buy |
22,525
+467
| +2% | +$5.05K | ﹤0.01% | 2905 |
|
|
2013
Q2 | $312K | Buy |
+22,058
| New | +$286K | ﹤0.01% | 2608 |
|
Other funds holding CCXI
RhumbLine Advisers's CCXI Position: Q4 2022 in Review
RhumbLine Advisers sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 94,082 shares — an estimated $4.86M sold.
RhumbLine Advisers first reported a position in CCXI in Q2 2013 and held it in 38 quarters. The position peaked at $4.86M in Q3 2022. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- RhumbLine Advisers reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- RhumbLine Advisers sold 94,082 ChemoCentryx, Inc. shares in Q4 2022, an estimated $4.86M.
- RhumbLine Advisers first reported a position in ChemoCentryx, Inc. in Q2 2013 and held it in 38 quarters.
- RhumbLine Advisers's ChemoCentryx, Inc. position peaked at $4.86M in Q3 2022.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on RhumbLine Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.